萊斯康製藥 LXRX 深 滬
交易中 05-18 10:16:24 美东时间
2.19
-0.040
-1.79%
華盛通- 最 高2.26
- 今 開2.22
- 成交量 41.26万股
- 最 低 2.1601
- 昨 收 2.23
- 總市值 97.28万
- 52周最高 2.53
- 市盈率 靜 --
- 換手率 0.09%
- 52周最低 0.615
- 委 比 61.56%
- 總股本 0.00亿
- 歷史最高 22.96
- 量 比 0.92
- 振 幅 4.48%
- 歷史最低 0.2836
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.
05-11 23:10
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals has secured a $100 million loan facility from Hercules Capital to enhance financial flexibility and support upcoming milestones. The initial $55 million will repay an existing loan, with additional tranches available upon achieving specific milestones. The facility features an 18-month interest-only period and a floating rate of prime plus 3.1%, maturing in 2030. Lexicon's CFO highlighted the deal's benefits for accessing ...
05-04 20:05
Lexicon Pharmaceuticals To Present Data From Its PROGRESS Phase 2b Trial Of Pilavapadin In Diabetic Peripheral Neuropathic Pain To Support Selection Of Pilavapadin 10 Mg As Optimal Dose For Phase 3 Development
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) supporting the selection of pilavapadin 10 mg
04-17 20:02
Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.
03-30 20:04
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With LX9851, An Oral Non-incretin Development Candidate, For Obesity And Associated Metabolic Disorders
In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide
03-23 19:38
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
LX9851, developed by Novo Nordisk and licensed from Lexicon Pharmaceuticals, is a first-in-class oral non-incretin candidate for obesity and metabolic disorders. Novo Nordisk has initiated a Phase 1 study, and Lexicon has received a second $10 million milestone payment, with potential total payments up to $1 billion plus royalties. Trials in 96 participants are evaluating safety, tolerability, and efficacy. LX9851 inhibits ACSL5 and activates the...
03-23 11:30
Lexicon Pharmaceuticals Says sotagliflozin Improves Cardiometabolic Outcomes In Type 1 Diabetes Regardless Of Kidney Function; New Analysis To Be Presented At ATTD 2026
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on
03-11 20:12
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
